NSEMonitoring Agency Report6d ago · 13 Nov 2026, 07:10 pm
Monitoring Agency Report
Manipal Health Enterprises Limited · MANIPALHOS
✦ AI SummaryResults
Manipal Health Enterprises Limited has submitted a Monitoring Agency Report for the quarter ended September 30, 2026, as per SEBI regulations. The report pertains to the utilization of the Initial Public Offer (IPO) proceeds.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Monitoring Agency Report
Attachments (1)
📄pdf
Download →
9632000477_13112026190832_Monitoring_Agency_Report_-Q2FY27_Signed.pdf
View document text
Date: November 13, 2026
National Stock Exchange of India Limited, BSE Limited,
Exchange Plaza, C-1, Block G, 20th Floor, P.J. Towers,
Bandra Kurla Complex, Bandra (E), Dalal Street,
Mumbai – 400 051 Mumbai - 400001.
NSE Scrip Symbol: MANIPALHOS BSE Scrip Code: 544847
Subject: Monitoring Agency Report for the quarter ended September 30, 2026
Ref: Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015 and Regulation 41 of the Securities and Exchange
Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018
Dear Sir/Ma’am,
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, read with Regulation 41 of the SEBI (Issue of Capital and Disclosure
Requirements) Regulations, 2018, we hereby submit the Monitoring Agency Report issued by CARE
Ratings Limited, for the quarter ended September 30, 2026, in respect of utilisation of proceeds of the
Initial Public Offer of the Company.
The above announcements will also be uploaded on the website of the Company and can be accessed
using the link: https://www.manipalhospitals.com/mhel-company-announcements/
This intimation is being submitted for your information and records.
Thank you.
For Manipal Health Enterprises Limited
(Formerly Manipal Health Enterprises Private Limited)
Sathish K R
Company Secretary and Compliance Officer
Membership No.: A15203
MHE-Public
RATIN G
No.CARE/ARO/GEN/2026-27/1229
The Board of Directors
Manipal Health Ent rprises Limited
Toe Ann , 98/2, Rustom Bagh,
HA Airport Road,
Bang lore - 560017, Kamataka, India
Novemb r 13, 2026
Dear Sr/Ma'am,
We write n our capacity of Mon torn A ency ro th IPO for th mount agg n to Rs. 8,000 cror of th Comp ny
and refer to our du es st und r 1 of th S . urt • s Exch n 8o rd of Ind (Issu of C8pi t Olsdosur
Requirements) Regulat ons
are n los ng th on o n Ag ncy R port for the Quart r nded S ptember 30, 2026, as per
aforesa d SEBI Regu atons and on1 rin Agency Agreem nt d t d July 15, 2026
Request you o e sam on records.
Than ng you,
Yours fa thfully,
Komal Israni
Assistant director
ni r
Report of the Monitoring Agency
Name of the Issuer: Manipal Health Enterprises Limited
For quarter ended: September 30, 2026
Name of the Monitoring Agency: CARE Ratings Limited
(a) Deviation from the objects: Nil
(b) Range of Devlation: Not Applicable
Declaration:
We declare that this report provides an objectJve view of the utllization of the Issue proceeds In relation to the objects of
the issue based on the lnfonnation provided by the Issuer and Information obtained from sources bel eved by it to be
accurate and reliable. The MA does not perfonn an audit nd undertakes no independent verification of any information/
certifications/ statements it receives. This Report Is not Intended to create any legally binding obligations on the MA
which accepts no responsibility whatsoever, for toss or damage from the use of the said Information. The views and
opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner
whatsoever. Nothing mentioned in this report Is Intended to or should be construed as creating a fiduciary relationship
between the MA and any issuer or between the agency and any user of this report. The MA and Its affiliates also do not
act as an expert as defined under Section 2(38) of the Companies Act, 2013.
The MA or its affiliates may have credit rating or other commercial transactions wtth the entity to which the report
pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there
is no conflict of interest in such relationship/Interest while monitoring and reporting the utiflzatjon of the issue proceeds
by the issuer, or while undertaking credit rating or other commercial transactJons with the entity.
We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where
applicable. There are certain sections of the report under the title ''Comments of the Board of Directors", that shall be
captured by the Issuer's Management/ Audit Committee of the Board of Directors subsequent to the MA submitting their
report to the lssuer and before dissemination of the report through stock exchanges. These sections have not been
reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board .
Signature:
Name and designation of the Authorized Signatory: Komal Israni
Designation of Authorized person/Signing Authority: Assistant Director
1) Issuer Details:
Name of issuer
: Manlpal Health Enterprises Limited
Name of the promoter
: Dr. Ranjan Ramdas Pal, Manipal Global Health Services, MEMG International Limited, Kangto Investments Pte Ltd.,
Imperlus Healthcare Investments Limited and Kabru Investments Pte Ud.
Industry/sector to which it belongs
: Healthcare Industry
2) Issue Details
Issue Period
: July 29, 2026 to July 31, 2026
Type of issue (public/rights)
: Public (IPO)
Type of specified securities
: Equity shares
IPO Grading, if any
: Not ap pl ica ble
Issue size (in crore)
: Rs. 8,000 crore {Fresh Issue)
Note: The Company had offered 15,72,33,715 equity shares, comprising a fresh issue of 13,56,19,881 equity shares aggregating to ,8,000 crore and an offer for sale of 2,16,13,834
equity shares aggregating to ,1,275.22 crore, at an issue price of ,s90 per equity share. The fresh issue included 2,80,898 equity shares offered to eligible employees under the
employee reservation portion at a discount of Rs.56 per share (i.e. at an issue price of ,534 per equity share).
The overall issue was subscribed by approximately 4.90 times. Subsequently, the Company allotted 15,72,33,715 equity shares (comprising 13,56,19,881 equity shares under the fresh
issue and 2,16,13,834 equity shares under the offer for sale) aggregating to ,9,275.22 crore.
Particulars
Amount (in Rs. crore
Gross Proceeds received from the fresh issue
8,000.00
Less: Issue exoenses related to the fresh issueA
244.31
Net Procee-ds from the fresh issue available for utilization
7,755.69
A Related to fresh issue as mentioned in prospectus.
3) Details of the arrangement made to ensure the monitoring of 'issue proceeds:
Source of information / ce~ifi(:a~e>ns
Comments of -the r:co-mments of the
Particulars iR~ply. considered by .Monitoring Ag¢ricy for ·- -
MonitQring Ag~ncy 1Boar~ :of :,Directors
-preparation of report
Prospectus dated July 31, 2026, CA
certificate*, Management certificate, Bank
Whether all utilization is as per the disclosures in the Offer statements, CA certificate on issue
No comments
No comments
Document? expense~*, No Dues Certificate from the
lenders, select high value invoices related
to Issue e~- ..:..nses.
Whether shareholder approval has been obtained in case of
Prospectus, Management Certificate
material deviations# from expenditures disclosed In the Offer Not Applicable
Not Applicable
Not Applicable
Document?
Whether the means of finance for the disclosed objects of the No CA certificate, Management certificate
No comments
No comments
Source of iiiformation / certifications Comments of .the
1 1 'Comments of the
Particulars Reply considered ·t;y Monitoring Agen~ ;for . Board -of Directors
IMonitorir:ag Agency
preparation of report
issue have changed?
Is there any major deviation observed over the earlier monitoring
Not Applicable
aoency reoorts?
Whether all Government/statutory approvals related to the
Not Applicable
Not Applicable
Not applicable Prospectus
object(s) have been obtained?
Whether all arrangements pertaining to technical
No comments
No comments
Not Applicable CA certificate, Management certificate
assistance/oollaboration are in operation?
Are there any favorabJe/unfa vorable events affecting the viability
No comments
No comments
No CA certificate, Management certificate
of these object(s)?
Is there any other relevant information that may
[Showing first 8,000 characters — download PDF for full document]